Wednesday, August 06, 2025 10:12:38 AM
$36,90"we are at the bottom" Stock Repurchase Program. In August 2024, Exelixis’ Board of Directors authorized a stock repurchase program to acquire up to $500 million of the company’s common stock before December 31, 2025. In February 2025, the Board of Directors authorized the repurchase of up to an additional $500 million of the company’s common stock before December 31, 2025. Under these programs, as of June 30, 2025, Exelixis has repurchased $796.3 million of the company’s common stock, at an average price of $36.69 per share. Since the approval of the first stock repurchase program in March 2023, the weighted-average diluted common shares outstanding has decreased from 326.3 million shares to 284.4 million shares as of June 30, 2025. Stock repurchases under these programs may be made from time to time through a variety of methods, which may include open market purchases, in block trades, accelerated share repurchase transactions, exchange transactions, or any combination of such methods. The timing and amount of any stock repurchases under the stock repurchase programs will be based on a variety of factors, including ongoing assessments of the capital needs of the business, alternative investment opportunities, the market price of our common stock and general market conditions.
https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-second-quarter-2025-financial-results-and
https://ir.exelixis.com/news-releases/news-release-details/exelixis-announces-second-quarter-2025-financial-results-and
Recent EXEL News
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June • Business Wire • 05/27/2026 08:05:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/26/2026 08:09:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/22/2026 09:01:45 PM
- Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types • Business Wire • 05/21/2026 09:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/20/2026 08:31:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 10:58:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 10:58:43 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 10:58:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 10:58:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 10:58:25 PM
- Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer • Business Wire • 05/19/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 08:49:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 08:23:30 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/14/2026 08:30:50 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 11:03:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 11:03:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 11:03:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2026 11:03:32 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2026 08:39:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2026 08:36:04 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2026 08:07:20 PM
- Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May • Business Wire • 05/07/2026 08:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/05/2026 08:11:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/05/2026 08:07:51 PM
- Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update • Business Wire • 05/05/2026 08:05:00 PM
